These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 25047250)

  • 21. Effective treatment of leukemia cutis with combination of rituximab, cladribine, and cyclophosphamide in patient with B-cell chronic lymphocytic leukemia.
    Batycka-Baran A; Baran W; Dzietczenia J; Mazur G
    Ann Hematol; 2011 Aug; 90(8):979-80. PubMed ID: 20978760
    [No Abstract]   [Full Text] [Related]  

  • 22. R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia.
    Tonino SH; van Gelder M; Eldering E; van Oers MH; Kater AP
    Leukemia; 2010 Mar; 24(3):652-4. PubMed ID: 19956201
    [No Abstract]   [Full Text] [Related]  

  • 23. Second malignancies in chronic lymphocytic leukemia.
    Streu E
    Oncol Nurs Forum; 2014 Jan; 41(1):95-8. PubMed ID: 24368244
    [No Abstract]   [Full Text] [Related]  

  • 24. Novel immune-based treatment strategies for chronic lymphocytic leukemia.
    Wierda WG; Kipps TJ; Keating MJ
    J Clin Oncol; 2005 Sep; 23(26):6325-32. PubMed ID: 16155015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progress in the treatment of chronic lymphocytic leukemia: results of the German CLL8 trial.
    Molica S
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1333-40. PubMed ID: 21929307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variations on the fludarabine, cyclophosphamide, and rituximab combination in chronic lymphocytic leukemia therapy: what have we learned?
    Ahmadi T; Schuster SJ
    J Clin Oncol; 2009 Feb; 27(4):479-80. PubMed ID: 19075263
    [No Abstract]   [Full Text] [Related]  

  • 27. Changing the way we think about chronic lymphocytic leukemia.
    Lin TS; Grever MR; Byrd JC
    J Clin Oncol; 2005 Jun; 23(18):4009-12. PubMed ID: 15767640
    [No Abstract]   [Full Text] [Related]  

  • 28. Promising results Halt phase III studies of idelalisib.
    Inman S
    Am J Manag Care; 2014 Feb; 20(2 Spec No.):E9. PubMed ID: 25764575
    [No Abstract]   [Full Text] [Related]  

  • 29. Monoclonal antibody combinations in CLL: evolving strategies.
    Faderl S; O'Brien S; Keating MJ
    Best Pract Res Clin Haematol; 2006; 19(4):781-93. PubMed ID: 16997183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal failure secondary to leukemic infiltration of kidneys in CLL--a case report and review of literature.
    Uprety D; Peterson A; Shah BK
    Ann Hematol; 2013 Jan; 92(2):271-3. PubMed ID: 22875063
    [No Abstract]   [Full Text] [Related]  

  • 31. Richter's transformation of chronic lymphocytic leukemia.
    Giardino AA; O'Regan K; Jagannathan JP; Elco C; Ramaiya N; Lacasce A
    J Clin Oncol; 2011 Apr; 29(10):e274-6. PubMed ID: 21220587
    [No Abstract]   [Full Text] [Related]  

  • 32. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
    Fischer K; Cramer P; Busch R; Stilgenbauer S; Bahlo J; Schweighofer CD; Böttcher S; Staib P; Kiehl M; Eckart MJ; Kranz G; Goede V; Elter T; Bühler A; Winkler D; Kneba M; Döhner H; Eichhorst BF; Hallek M; Wendtner CM
    J Clin Oncol; 2011 Sep; 29(26):3559-66. PubMed ID: 21844497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Subcutaneous panniculitis-like T-cell lymphoma following treatment with rituximab and cyclophosphamide].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2013 Mar; 140(3):246-7. PubMed ID: 23466166
    [No Abstract]   [Full Text] [Related]  

  • 34. Individualized fludarabine-based regimen in elderly patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Guo B; Zhu HL; Fan H; Li SX; Lu XC; Lin J; Ran HH; Zhai B; Yang Y
    Adv Ther; 2012 Feb; 29(2):178-86. PubMed ID: 22249944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Toxicodermia by bendamustine: development of a desensization protocol].
    Sangrador Pelluz C; Luis Hidalgo MM; Martínez García M; Pérez-Serrano Lainosa MD; Soler Company E
    Farm Hosp; 2013; 37(5):421-3. PubMed ID: 24128107
    [No Abstract]   [Full Text] [Related]  

  • 36. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
    Fischer K; Cramer P; Busch R; Böttcher S; Bahlo J; Schubert J; Pflüger KH; Schott S; Goede V; Isfort S; von Tresckow J; Fink AM; Bühler A; Winkler D; Kreuzer KA; Staib P; Ritgen M; Kneba M; Döhner H; Eichhorst BF; Hallek M; Stilgenbauer S; Wendtner CM
    J Clin Oncol; 2012 Sep; 30(26):3209-16. PubMed ID: 22869884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic lymphocytic leukaemia. Current strategy and new perspectives of treatment.
    Rai KR
    Haematologica; 1999 Jun; 84 Suppl EHA-4():94-5. PubMed ID: 10907481
    [No Abstract]   [Full Text] [Related]  

  • 38. Management of elderly patients with chronic lymphocytic leukemia in the era of targeted therapies.
    Ysebaert L; Feugier P; Michallet AS
    Curr Opin Oncol; 2015 Sep; 27(5):365-70. PubMed ID: 26154708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bendamustine in chronic lymphocytic leukemia and refractory lymphoma.
    Rummel MJ
    Semin Hematol; 2008 Jul; 45(3 Suppl 2):S7-10. PubMed ID: 18760709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma.
    Civallero M; Cosenza M; Bari A; Sacchi S
    Expert Opin Investig Drugs; 2011 Aug; 20(8):1029-31. PubMed ID: 21702717
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.